Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996038166 - SERUM AMYLOID A PROTEIN

Publication Number WO/1996/038166
Publication Date 05.12.1996
International Application No. PCT/CA1996/000404
International Filing Date 03.06.1996
Chapter 2 Demand Filed 17.12.1996
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
CPC
A61K 38/1709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
1709from mammals
Applicants
  • QUEEN'S UNIVERSITY AT KINGSTON [CA]/[CA]
Inventors
  • KISILEVSKY, Robert
Agents
  • VANDENHOFF, Deborah, G.
Priority Data
08/458,05401.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SERUM AMYLOID A PROTEIN
(FR) PROTEINE AMYLOIDE SERIQUE A
Abstract
(EN)
A method is provided for potentiating the release and collection of cholesterol from inflammatory or atherosclerotic sites $i(in vivo), the method including the steps of increasing the affinity of high-density lipoprotein for macrophages by administering to a patient an effective amount of a composition comprising a compound selected from the group consisting of native serum amyloid A (SAA) and a ligand having SAA properties thereby increasing the affinity of high density lipoprotein (HDL) for macrophages and potentiating release and collection of cholesterol.
(FR)
L'invention porte sur un procédé permettant de potentialiser la libération et le recueil du cholestérol à partir de sites inflammatoires ou athéroscléreux $i(in vivo). Le procédé consiste à augmenter l'affinité des lipoprotéines de haute densité pour les macrophages par administration à un patient d'une dose efficace d'une composition comprenant un composé choisi dans le groupe constitué d'amyloïde sérique A natif (SAA) et d'un ligand aux propriétés SAA. Il en résulte une augmentation de l'affinité des lipoprotéines de haute densité (HDL) pour les macrophages et une potentialisation de la libération et du recueil du cholestérol.
Also published as
Latest bibliographic data on file with the International Bureau